D.E. Shaw & Co’s Soleno Therapeutics SLNO Stock Holding History

D.E. Shaw & Co’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,247	Closed	-$1.01M	–	5184
2026 Q1	$1.01M	Buy	30,247 +24,480	+424%	+$960K	﹤0.01%	3433
2025 Q4	$267K	Sell	5,767 -1,999	-26%	-$110K	﹤0.01%	4203
2025 Q3	$525K	Sell	7,766 -106,924	-93%	-$7.93M	﹤0.01%	3846
2025 Q2	$9.61M	Buy	114,690 +98,018	+588%	+$7.34M	0.01%	1523
2025 Q1	$1.19M	Buy	+16,672	New	+$812K	﹤0.01%	2984

D.E. Shaw & Co's SLNO Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 30,247 shares — an estimated $1.01M sold.

D.E. Shaw & Co first reported a position in SLNO in Q1 2025 and held it in 5 quarters. The position peaked at $9.61M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

D.E. Shaw & Co reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
D.E. Shaw & Co sold 30,247 Soleno Therapeutics shares in Q2 2026, an estimated $1.01M.
D.E. Shaw & Co first reported a position in Soleno Therapeutics in Q1 2025 and held it in 5 quarters.
D.E. Shaw & Co's Soleno Therapeutics position peaked at $9.61M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.